https://www.selleckchem.com/pr....oducts/l-histidine-m
The 5-year OS of patients with lymph node (LN) metastases and unknown primary site (UPM) was 45% . 21% of patients with synchronous LN metastasis. Patients with SLN tumour burden 0.3 mm had 5-year OS similar to SLN negative patients (86% . 85%; p = 0.926). The 5-year OS of patients with burden 1.0 mm was similar to the MLNM group (49% . 47%; p = 0.28. Stage III melanoma patients is a heterogeneous group with significant OS differences. CLND after positive SLNB might still remain a method of
Like
Comment
Share
